Literature DB >> 6752292

The pathogenic mechanisms of blister formation in bullous pemphigoid.

K Naito, S Morioka, H Ogawa.   

Abstract

Normal human skin was cultured with sera, IgG fractions, and blister fluids (BF) from patients with bullous pemphigoid. Antibody binding (IgG) was observed by immunofluorescence techniques at the dermal-epidermal junction of all skin explants culture with sera, IgG fractions, and BF. Dermal-epidermal separation was observed only in the skin explants cultured with BF. Dermal-epidermal separation was observed in 19 out of 20 explants cultured with BF obtained from fresh bullae. In addition, dermal-epidermal separation can be produced in vivo 6 hr after the injection of BF into the dorsal skin of Hartley guinea pigs. Dermal-epidermal separation was not observed in skin explants cultured with heat-inactivated (56 degrees, C 30 min) BF, although antibody binding was observed. In addition, dermal-epidermal separation did not occur when the BF were preincubated with rabbit antihuman C1, C3, C4, and C5 antibodies. These observations suggested that both antibody and complement were essential for the production of dermal-epidermal separation. Since patient sera failed to produce dermal-epidermal separation, other factor(s) present in BF but absent from serum might be necessary for the production of dermal-epidermal separation. The addition of the proteinase inhibitors, pepstatin, EDTA, and soy bean trypsin inhibitor, did not inhibit the formation of dermal-epidermal separation. In contrast, the presence of alpha 2-macroglobulin inhibited dermal-epidermal separation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6752292     DOI: 10.1111/1523-1747.ep12500082

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analyses of the heterogeneity of anti-BMZ antibodies in BP sera using them.

Authors:  T Sugi; T Hashimoto; T Hibi; T Nishikawa
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

2.  1-2B7B: monoclonal antibody reacting to the 120 kDa polypeptide component of human epidermal hemidesmosomes.

Authors:  X M Zhang; Y Horiguchi; M Ueda; T Yoshiki; S Imamura
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

3.  Deposition of eosinophil granule proteins precedes blister formation in bullous pemphigoid. Comparison with neutrophil and mast cell granule proteins.

Authors:  L Borrego; B Maynard; E A Peterson; T George; L Iglesias; M S Peters; W Newman; G J Gleich; K M Leiferman
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

4.  Human autoantibodies against the 230-kD bullous pemphigoid antigen (BPAG1) bind only to the intracellular domain of the hemidesmosome, whereas those against the 180-kD bullous pemphigoid antigen (BPAG2) bind along the plasma membrane of the hemidesmosome in normal human and swine skin.

Authors:  A Ishiko; H Shimizu; A Kikuchi; T Ebihara; T Hashimoto; T Nishikawa
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

5.  92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen.

Authors:  M Ståhle-Bäckdahl; M Inoue; G J Guidice; W C Parks
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

6.  Elevated expression and release of tissue-type, but not urokinase-type, plasminogen activator after binding of autoantibodies to bullous pemphigoid antigen 180 in cultured human keratinocytes.

Authors:  E Schmidt; B Wehr; E M Tabengwa; S Reimer; E-B Bröcker; D Zillikens
Journal:  Clin Exp Immunol       Date:  2004-03       Impact factor: 4.330

7.  Lymphotoxin detected in the blister fluid of bullous pemphigoid patients.

Authors:  E W Jeffes; R S Yamamoto; A R Ahmed; G A Granger
Journal:  J Clin Immunol       Date:  1984-01       Impact factor: 8.317

8.  Expression of HLA-DR (Ia like) antigen on epidermal keratinocytes in human dermatoses.

Authors:  I A Lampert
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.